6 Dimensions Capital
PE-backed Brii Bioscience pursues Hong Kong listing
Brii Biosciences, a three-year-old Chinese biotech start-up that has raised approximately $415 million in private funding from the likes of Sequoia Capital China, Boyu Capital, and Yunfeng Capital, has filed for a Hong Kong IPO.
China biotech player Gracell raises $100m Series C
Wellington Management, OrbiMed and Morningside Ventures have led a $100 million Series C round for Gracell Biotechnologies, a China-based developer of cancer treatments.
Ocumension climbs on debut after $184m Hong Kong IPO
Ocumension Therapeutics, a Chinese drug developer targeting eye diseases that counts Boyu Capital and Temasek Holdings among its backers, posted a 152% gain on debut following a HK$1.5 billion ($200 million) Hong Kong IPO.
China GPs back US health-tech player in $22m Asia push
China’s 6 Dimensions Capital and Yonghua Capital have joined a $22 million Series C round for US-based Ultivue that will help the medical technology developer expand into Asia.
Cancer drug developer Innovent Biologics files for HK IPO
Innovent Biologics, a Chinese drug developer company with a number of PE backers, has filed for an IPO in Hong Kong under recently introduced rules allowing listings by biotech companies with no revenue or profits.
Hua Medicine files for HK IPO under biotech fastrack
Hua Medicine, a Chinese drug developer player that simultaneously closed its Series D and E funding rounds in March, has become the second company to file for a Hong Kong IPO under rules that allow zero revenue biotech businesses to go public.
Brii Biosciences gets $260m for China expansion
A group of VCs, including Sequoia Capital, have committed $260 million to Brii Biosciences, a China and US-based healthcare start-up executing a number of China-focused growth initiatives.
Chinese VCs join $300m round for US, Hong Kong-based Grail
Ally Bridge Group, Hillhouse Capital and 6 Dimensions Capital have co-led a $300 million Series C round for Grail, a biotechnology development firm based in Hong Kong and the US.
GIC leads $260m round for China’s CStone Pharma
Singapore’s GIC Private has led a $260 million Series B investment in China’s CStone Pharmaceuticals. The round, completed within two months, is said to be the largest biopharma Series B in the country to date.
China’s Hua Medicine gets $117m
Hua Medicine, a Chinese clinical-stage biotechnology company, has closed a combined Series D and Series E funding round at $117.4 million with support from a group of VCs.
Chinese GPs back AstraZeneca spin-out
A consortium led by Boyu Capital, 6 Dimensions Capital and Hillhouse Capital will invest up to $250 million in Viela Bio, a pharmaceutical research and development company being spun out from AstraZeneca.
Asia VCs invest $10m in US-Singapore biotech player
A group of VCs led by China’s 6 Dimensions Capital and Sino-US investor Danhua Capital (DHVC) has committed $10 million to US and Singapore-based Engine Biosciences.
China’s AnchorDx raises $28m Series B
AnchorDx, a China-based company that develops new clinical diagnosis products based on next-generation sequencing (NGS) technology, has raised $28 million in a Series B round led by 6 Dimensions Capital and Sijia Jianxin Fund.